by Maria Zannes | Oct 12, 2018 | News
OCTOBER 10, 2018 As published in the San Antonio Business Journal By W. Scott Bailey – Senior Reporter, San Antonio Business Journal BioAffinity Technologies, a San Antonio-based biotech, has struck a deal with another local company, Precision Pathology Services, to...
by Maria Zannes | Oct 12, 2018 | Press Releases
OCTOBER 10, 2018 (San Antonio, TX) bioAffinity Technologies, a privately held biotech company, today announced a licensing agreement with Precision Pathology Services for the continued development and commercial sale of CyPath® Lung as a Laboratory Developed Test...
by Maria Zannes | Sep 22, 2018 | Press Releases
SEPTEMBER 18, 2018 (San Antonio, TX) bioAffinity Technologies, a privately held biotech company, today announced that the Icahn School of Medicine at Mount Sinai (ISMMS) in New York, NY, will be a clinical collection site for the Company’s test validation trial of...
by Maria Zannes | Aug 1, 2018 | Press Releases
JULY 31, 2018 (San Antonio, TX) bioAffinity Technologies, a privately held biomedical company advancing breakthrough cancer diagnostics and therapeutics, is pleased to welcome Mohsin Y. Meghji, managing partner of M-III Partners L.P. (M-III), to its Board of...
by Maria Zannes | Jul 24, 2018 | News
JULY 20, 2018 As published in GenomeWeb’s 360Dx By Leo O’Connor NEW YORK – BioAffinity Technologies has begun clinical validation of a test for the early detection of lung cancer that uses flow cytometry and detects porphyrin molecules in sputum samples. The San...
